EUCTR2014-001715-39-Outside-EU/EEA进行中（未招募）不适用
Study of CYD Dengue Vaccine in Healthy Children and Adolescents in South America
Sanofi Pasteur SA0 个研究点目标入组 150 人开始时间: 2014年5月26日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 150
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1) Aged 9 to 16 years on the day of inclusion
- •2) Subject in good health, based on medical history and physical examination
- •3) Provision of assent form/informed consent form signed by the subject and by the parent(s) or another legally acceptable representative
- •4) Subject able to attend all scheduled visits and to comply with all trial procedures
- •5) For a female subject of child-bearing potential, avoid becoming pregnant (use of an effective method of contraception or abstinence) for at least 4 weeks prior to first vaccination until at least 4 weeks after the last vaccination
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 150
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1) Personal or family history of thymic pathology (thymoma), thymectomy, or myasthenia
- •2) For a female subject of child-bearing potential, known pregnancy or positive urine pregnancy test at V01
- •3) Participation in another clinical trial investigating a vaccine, drug, medical device, or a medical procedure in the 4 weeks preceding the first trial vaccination
- •4) Breast-feeding woman
- •5) Planned participation in another clinical trial during the present trial period
- •6) Known or suspected congenital or acquired immunodeficiency, immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months, or long-term systemic corticosteroids therapy
- •7) Known systemic hypersensitivity to any of the components of any of the trial vaccines or history of a life-threatening reaction to any of the trial vaccines or to a vaccine containing any of the same substances
- •8) Chronic illness at a stage that could interfere with trial conduct or completion, in the opinion of the Investigator
- •9) Current alcohol abuse or drug addiction that may interfere with the subject’s ability to comply with trial procedures
- •10) Receipt of blood or blood-derived products in the preceding 3 months that might interfere with the assessment of immune response
- •11) Receipt of any vaccine in the 4 weeks preceding the first trial vaccination
- •12) Planned receipt of any vaccine in the 4 weeks following the first trial vaccination
- •13) Subject deprived of freedom by administrative or court order, or in an emergency setting, or hospitalized without his/her consent
- •14) Febrile illness (temperature = 38.0°C) or moderate or severe acute illness/infection on the day of vaccination, according to Investigator’s judgment
研究者
相似试验
进行中（未招募）
不适用
Study of Sanofi Pasteur's dengue vaccine in healthy toddlers Aged 12 to 15 Months in the PhilippinesPrevention of symptomatic dengue diseaseEUCTR2014-001694-14-Outside-EU/EEASanofi Pasteur SA210
进行中（未招募）
不适用
Study of Sanofi Pasteur's dengue vaccine in Healthy Children Aged 4 to 11 Years in Thailand to evaluate its efficacyPrevention of symptomatic dengue diseaseEUCTR2014-001710-25-Outside-EU/EEASanofi Pasteur SA4,002
进行中（未招募）
不适用
Study of Sanofi Pasteur's Dengue Vaccine in Healthy Children Aged 2 to 11 Years in MalaysiaPrevention of symptomatic dengue diseaseEUCTR2014-001717-11-Outside-EU/EEASanofi Pasteur SA250
已完成
2 期
A Study of Dengue Vaccine in Healthy Toddlers Aged 12 to 15 Months in the PhilippinesDengue Hemorrhagic FeverDengue FeverNCT01064141Sanofi210
已完成
2 期
Efficacy and Safety of Dengue Vaccine in Healthy ChildrenDengue VirusDengue DiseasesDengue FeverDengue Hemorrhagic FeverNCT00842530Sanofi Pasteur, a Sanofi Company4,002